148 related articles for article (PubMed ID: 7606879)
21. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study.
Anraku M; Kitamura K; Shintomo R; Takeuchi K; Ikeda H; Nagano J; Ko T; Mera K; Tomita K; Otagiri M
Clin Biochem; 2008 Oct; 41(14-15):1168-74. PubMed ID: 18692036
[TBL] [Abstract][Full Text] [Related]
22. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
23. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
24. [Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis].
Vanková S; Safárová R; Horácková M; Herink J; Rychlík I; Bahbouh R; Půtová I
Cas Lek Cesk; 2001 Apr; 140(7):209-13. PubMed ID: 11374225
[TBL] [Abstract][Full Text] [Related]
25. [Iron supplementation during erythropoietin therapy in patients on hemodialysis].
Svára F; Sulková S; Kvasnićka J; Polakovic V
Vnitr Lek; 1996 Dec; 42(12):849-52. PubMed ID: 9072885
[TBL] [Abstract][Full Text] [Related]
26. Monitoring of iron requirements in renal patients on erythropoietin.
Anastassiades EG; Howarth D; Howarth J; Shanks D; Waters HM; Hyde K; Geary CG; Yin JA; Gokal R
Nephrol Dial Transplant; 1993; 8(9):846-53. PubMed ID: 8255518
[TBL] [Abstract][Full Text] [Related]
27. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
Riedel MK; Morgenstern T
Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
[TBL] [Abstract][Full Text] [Related]
28. [Role of iron deficiency in erythropoietin sensitivity in dialysis patients with elevated C-reactive protein].
Martone M; Zanchi R; Panzetta G
G Ital Nefrol; 2003; 20(1):31-7. PubMed ID: 12647284
[TBL] [Abstract][Full Text] [Related]
29. Serum ferritin and tissue iron in anemic dialysis patients.
Bárány P; Eriksson LC; Hultcrantz R; Pettersson E; Bergström J
Miner Electrolyte Metab; 1997; 23(3-6):273-6. PubMed ID: 9387132
[TBL] [Abstract][Full Text] [Related]
30. Assessment of iron deficiency in chronic hemodialysis patients: investigation of cutoff values for reticulocyte hemoglobin content.
Mitsuiki K; Harada A; Miyata Y
Clin Exp Nephrol; 2003 Mar; 7(1):52-7. PubMed ID: 14586744
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of low-dose i.v. iron therapy in haemodialysis patients.
Park J; Chang JW; Lee JS; Chung HC; Yang WS; Lee SK; Park SK; Park JS
Nephrology (Carlton); 2009 Dec; 14(8):716-21. PubMed ID: 20025679
[TBL] [Abstract][Full Text] [Related]
32. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease.
Ferrari P; Mallon D; Trinder D; Olynyk JK
Nephrology (Carlton); 2010 Apr; 15(3):344-9. PubMed ID: 20470305
[TBL] [Abstract][Full Text] [Related]
33. The plasma ferritin level as a reliable index of body iron stores following intravenous iron dextran.
Jacobs P; Dommisse J
J Med; 1982; 13(4):309-21. PubMed ID: 6957530
[TBL] [Abstract][Full Text] [Related]
34. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients.
Baldus M; Salopek S; Möller M; Schliesser J; Klooker P; Reddig J; Gansert U; Brass H
Nephrol Dial Transplant; 1996 Mar; 11(3):486-91. PubMed ID: 8710158
[TBL] [Abstract][Full Text] [Related]
35. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
Ahluwalia N; Skikne BS; Savin V; Chonko A
Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
[TBL] [Abstract][Full Text] [Related]
36. [Reappearance of pica symptoms during erythropoietin treatment].
Duclos J
Rev Med Chil; 1992 Mar; 120(3):296-9. PubMed ID: 1342483
[TBL] [Abstract][Full Text] [Related]
37. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
Tarng DC; Huang TP; Chen TW
Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
[TBL] [Abstract][Full Text] [Related]
38. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia.
Tarng DC; Wei YH; Huang TP; Kuo BI; Yang WC
Kidney Int; 1999 Jun; 55(6):2477-86. PubMed ID: 10354297
[TBL] [Abstract][Full Text] [Related]
39. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients.
Chang CH; Chang CC; Chiang SS
Clin Nephrol; 2002 Feb; 57(2):136-41. PubMed ID: 11863124
[TBL] [Abstract][Full Text] [Related]
40. [Serum ferritin and iron therapy in childhood. Experiences with iron resin adsorbate (author's transl)].
Weippl G; Kaltwasser JP
Klin Padiatr; 1980 Jul; 192(4):304-8. PubMed ID: 7192762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
